SDC 1. Demographical, clinical and surgical characteristics of cohort patients.
Characteristics Number of patients,
(%).
Total N=65 Age (Median, IQR), years 28 (20-44) Gender
- Male
- Female
29 (44.6%) 36 (55.4%) Body Mass Index (Median, IQR) 29 ± 5.5 Smoking status
- Yes
- No
36 (55.4%) 29 (44.6%) Hypertension
- Yes
- No
10 (15.4%) 55 (84.6%) Diabetes
- Yes
- No
7 (10.8%) 58 (89.2%) Charlson comorbidity index (Average,
range)
0.53 (0-6) Number of lesions (Median, Range) 2 (1-5) Location of lesions
- Groin - Axilla - Breast - Abdomen - Thigh
- Infra-gulteal fold - Perineum - Labia majora - Nape
- Mons pubis - Clavicle
N=153 (100%) 63 (41.2%) 60 (39.2%) 10 (6.5%) 5 (3.3%) 4 (2.6%) 3 (2.0%) 2 (1.3%) 2 (1.3%) 1 (0.65%) 1 (0.65%) 1 (0.65%) Average lesion size (cm) , Median ±SD
(Range)
5.81 ± 5.49 (1-36) Total Body Surface Area affected by lesion
(Median, Range)
0.17% ± 0.87 (0.01- 6.22)
Hurley stage of lesion
- 1
- 2 - 3
N=65 (100%) 14 (21.5%) 43 (66.1%) 8 (12.3%) Previous drainage of lesion 26 (40%) Pre-operative treatment with systemic
antibiotics
- Clindamycin - Rifampicin
N=90 31 (34.4%) 28 (31.1%)
- Cephalexin - Dapsone - Minocycline - Doxycycline - Augmentin - Ciprofloxacin - Ampicillin
8 (8.9%) 6 (6.7%) 6 (6.7%) 4 (4.4%) 4 (4.4%) 2 (2.2%) 1 (1.1%) Pre-operative treatment with topical
antibiotics
- Clindamycin - Zindaclin 1%
- Triclosan
- Chloramphenicol
N=26 (100%) 16 (61.5%) 6 (23.1%) 3 (11.5%) 1 (3.8%) Pre-operative treatment with oral retinoids
- Isotretinoin
N=6 (100%) 6 (100%) Surgical procedure
- Resection with primary closure - Resection with split-thickness skin
graft
- Resection with secondary closure - Debridement
- Unroofing
- Flap advancement - Abdominoplasty - Internal thigh lift
N=77 (100%) 44 (57.1%) 20 (26.0%) 2 (2.6%) 5 (6.5%) 1 (1.3%) 5 (6.5%) 2 (2.6%) 3 (3.9%) Post-operative topical antibiotic treatment
- Fusidic acid - Mupirocin
N=53 (100%) 36 (67.9%) 17 (32.1%) Post-operative systemic antibiotic
treatment
- Cephalexin - Clindamycin - Rifampicin - Vancomycin - Augmentin - Ciprofloxacin
- Amoxicillin-clavulonic acid - Pipercillin-tazobactam - Ertapenem
N= 50 (100%) 35 (70%) 10 (20%) 3 (6%) 3 (6%) 2 (4%) 2 (4%) 2 (4%) 1 (2%) 1 (2%) Complications
- Surgical site infection - Bleeding
- Failure of skin graft - Hypertrophic scarring
N=11 (100%) 7 (63.6%) 2 (18.2%) 1 (9.1%) 1 (9.1%) Recurrence
- Yes
- No
32 (49.2%) 33 (50.8%)
Time to first recurrence (Median ± SD, Range), days
420 ± 234 (15-878.6) Total number of surgeries
- 1
- 2 - 3 - 4 - 5 - 6 - 7 - 8
N=65 (100%) 47 (72.3%) 9 (13.8%) 2 (3.1%) 2 (3.1%) 2 (3.1%) 1 (1.5%) 1 (1.5%) 1 (1.5%)
Follow up (Median, Range), days 466.5 (90-6715)
